Daily non-political popular news in brief.

STEP HIV vaccine study to be unblinded

Merck & Co., Inc. and the HIV Vaccine Trials Network today announced that study volunteers in the STEP study of Merck's HIV vaccine will be told whether they received vaccine or placebo, and all study volunteers will be encouraged to continue to return to their study sites on a regular basis for ongoing risk reduction counseling and study-related tests.

Read more »

Keywords: step, hiv, vaccine, study, unblinded

« Previous | Next »

Similar news on "STEP HIV vaccine study to be unblinded":

1. The release of new data from the HVTN 502 HIV vaccine study
   11-07-2007 · EurekAlert!
   The new analyses revealed today from the STEP HIV vaccine clinical trial are both disappointing and puzzling. At this time, the data offer no clear explanations as to why the vaccine showed no measurable efficacy or why among individuals with background immunity to the adenovirus vector, there were more HIV infections in the vaccinees as compared to those in the placebo group. Analyses of the STEP data are continuing, and it will take some time before we fully understand these results.
   Similar news · Read more »
   
2. Virus used to create experimental HIV vaccines directly impairs the immune response
   11-15-2007 · EurekAlert!
   Leading efforts to create an HIV vaccine have hinged on the use of viruses as carriers for selected elements of the HIV virus. Recently, however, evidence has emerged that some of these so-called viral vector systems may undermine the immune system and should not be used for vaccine development. Now, a new study from scientists at the Wistar Institute provides strong support for the idea that some viral-vector vaccines may cause more harm than good.
   Similar news · Read more »
   
3. Common virus may help doctors treat deadly brain tumors
   10-22-2007 · EurekAlert!
   A common human virus may prove useful in attacking the deadliest form of brain tumors, according to a study by researchers at Duke's Preston Robert Tisch Brain Tumor Center. The researchers said the finding is an important step in developing a vaccine that can attack the tumors by enlisting the help of the body's immune system.
   Similar news · Read more »
   
4. Chronic HIV-1 infection frequently fails to protect against superinfection
   11-15-2007 · EurekAlert!
   Natural HIV-1 infection does not always elicit a protective immune response, according to a new study published Nov. 16 in PLoS Pathogens. The team of researchers show how HIV-1 vaccines may not be as reliable against superinfection as once thought. This study suggests that immune responses found in natural HIV-1 infection may not be the best path to an effective HIV-1 vaccine.
   Similar news · Read more »
   
5. Hopkins joins Ugandan researchers to study pediatric AIDS vaccine
   10-13-2006 · EurekAlert!
   Scientists at Makerere University, in Kampala, Uganda, along with scientists from Johns Hopkins and other institutions worldwide, have begun the first clinical safety trial in Africa of a vaccine to prevent mother-to-child transmission of HIV through breastfeeding.
   Similar news · Read more »
   
6. Penn researchers find monkeys able to fend off AIDS-like symptoms with enhanced HIV vaccine
   11-20-2007 · EurekAlert!
   Researchers at the University of Pennsylvania School of Medicine have discovered that using an immune system gene to enhance a vaccine used to study HIV in macaque monkeys provides the animals with greater protection against simian HIV than an unmodified vaccine.
   Similar news · Read more »
   
7. First large-scale HIV vaccine trial in South Africa opens
   02-08-2007 · EurekAlert!
   A large-scale clinical trial of a candidate HIV vaccine -- which previously showed promise in smaller studies in the United States and elsewhere -- has now opened in South Africa. The study plans to enroll up to 3,000 HIV-negative men and women, making it the largest African HIV vaccine trial to date.
   Similar news · Read more »
   
8. Africa's first large-scale HIV vaccine study launches
   02-08-2007 · EurekAlert!
   The launch of the first large-scale study to evaluate a candidate HIV vaccine on the African continent was announced today by study collaborators in the United States and South Africa. The trial will involve up to 3,000 participants at five sites throughout South Africa and is expected to continue for four years.
   Similar news · Read more »
   
9. New study suggests potential for a broadly-protective HIV vaccine
   05-29-2007 · EurekAlert!
   New research conducted at the Uniformed Services University of the Health Sciences (USU) suggests that it may be possible to develop a vaccine that protects against the myriad strains of the HIV virus. HIV is extremely variable, so an effective vaccine may need to stimulate the body to produce cross-reactive antibodies that will neutralize multiple viral strains. These results demonstrate that induction of truly broad-spectrum neutralizing antibodies may be an achievable goal.
   Similar news · Read more »
   
10. Novel genetics research advances possibility of HIV vaccine
    07-05-2007 · EurekAlert!
    A pioneering collaborative study has discovered how the HIV virus evades the human body's immune system. The research collaborative -- involving scientists from the British Columbia Centre for Excellence in HIV/AIDS, Massachusetts General Hospital, Microsoft Research and Los Alamos National Laboratory -- used highly computer-intensive, cutting-edge statistical research methods to investigate how the HIV virus mutates to escape the body's immune system.
    Similar news · Read more »